Washington, D.C. 20549

                                  SCHEDULE 13G
                    Under the Securities Exchange Act of 1934

                            PRO-PHARMACEUTICALS, INC.
                                (Name of Issuer)

                          Common Stock, $.001 par value
                         (Title of Class of Securities)

                                 (CUSIP Number)

     August 13, 2001 (date of registration of Common Stock under Sec. 12(g))
             (Date of Event which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

                                / / Rule 13d-1(b)
                                / / Rule 13d-1(c)
                                /x/ Rule 13d-1(d)

CUSIP No. 74267T109 Page 2 of 5 - ------ ------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Offer Binder S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON - ------ ------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ___ (b) X --- - ------ ------------------------------------------------------------------------- 3 SEC USE ONLY - ------ ------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States - --------------------- ------ --------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER 1,245,878 SHARES ------ --------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER 0 OWNED BY ------ --------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER 1,245,878 REPORTING ------ --------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER 0 WITH - ------ ------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,245,878 - ------ ------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES --- - ------ ------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.0% - ------ ------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON IN - ------ -------------------------------------------------------------------------

CUSIP No. 74267T109 Page 3 of 5 Item 1(a). Name of Issuer: Pro-Pharmaceuticals, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 189 Wells Avenue, Suite 200 Newton, MA 02459 Item 2(a). Name of Person Filing: Offer Binder Item 2(b). Address of Principal Business Office or, if None, Residence: c/o Pasquale via Settembrini 14/A San Mariano 06073 Corciano (PG) Italy Item 2(c). Citizenship: United States Item 2(d). Title of Class of Securities: Common Stock, $.001 par value Item 2(e). CUSIP Number: 74267T109 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) / / Broker or dealer registered under Section 15 of the Exchange Act. (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act. (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) / / Investment company registered under Section 8 of the Investment Company Act. (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act. (j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Not Applicable

CUSIP No. 74267T109 Page 4 of 5 Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 1,245,878* (b) Percent of class: 8.0%** (c) Number of shares as to which the person has: (i) Sole power to vote or direct the vote: 1,245,878 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 1,245,878 (iv) Shared power to dispose or to direct the disposition of: 0 * Includes 10,411 shares owned by Mr. Binder's wife, as to which Mr. Binder disclaims beneficial ownership. ** Based on 15,538,409 shares outstanding as of January 15, 2002. Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable

CUSIP No. 74267T109 Page 5 of 5 Item 10. Certification. Not Applicable SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: January 16, 2002 /s/ Offer Binder -------------------------- Offer Binder